A 2-Week Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Anti-Inflammatory Effects of Low, Medium, and High Dose Mometasone Furoate/Formoterol Fumarate MDI Formulation and Medium Dose Mometasone Furoate DPI and MDI Formulations in Adults and Adolescents With Persistent Allergic Asthma

NCT00635882 Phase 2 COMPLETED Results posted

This is a 2-week double-blind, placebo-controlled, parallel group study comparing the anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) formulation and medium dose mometasone furoate (MF) dry powder inhaler (DPI) and MDI formulations in adults and adolescents with persistent allergic asthma.

Details

Lead sponsor	Organon and Co
Phase	Phase 2
Status	COMPLETED
Enrolment	93
Start date	2008-02
Completion	2009-06

Conditions

• Asthma
• Airway Inflammation

Interventions

• mometasone furoate/formoterol 100/10 mcg
• mometasone furoate/formoterol 200/10 mcg
• mometasone furoate/formoterol 400/10 mcg
• MF DPI 200 mcg
• MF MDI 200 mcg
• Placebo

Primary outcomes

• Mean Percent Change From Baseline to Day 14 in Exhaled Nitric Oxide (eNO) Parts Per Billion (Ppb) — Baseline to Day 14